StonvexLoading…
StonvexStonvexStonvexCore line items from ACMR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $901.31M | $782.12M | $557.72M | $388.83M |
Operating Income | $109.43M | $151.00M | $95.84M | $59.03M |
Net Income | $94.08M | $103.63M | $77.35M | $39.26M |
EPS (Diluted) | $1.37 | $1.53 | $1.16 | $0.59 |
Total Assets | $2.87B | $1.86B | $1.49B | $1.24B |
Total Liabilities | $941.68M | $759.82M | $564.75M | $423.33M |
Cash & Equivalents | $757.37M | $407.44M | $182.09M | $247.95M |
Free Cash Flow OCF − CapEx | $-66.61M | $69.99M | $-137.20M | $-153.29M |
Shares Outstanding | 67.31M | 66.24M | 64.87M | 65.34M |